Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 17/20 | 1.00 |
| ▸ | BECN1 | Q14457 | 17/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23268914 | 0.93 | BCL2 (0.86) | BCL2BECN1PKMALDH1A1MEN1 | |
| SCHEMBL23269265 | 0.92 | BCL2 (1.00) | BCL2BECN1PKMALDH1A1 | |
| SCHEMBL23269361 | 0.92 | BCL2 (1.00) | BCL2BECN1PKMALDH1A1MEN1 | |
| SCHEMBL23268988 | 0.92 | BCL2 (1.00) | BCL2BECN1PKMALDH1A1 | |
| SCHEMBL23269368 | 0.92 | BCL2 (1.00) | BCL2BECN1PKMALDH1A1 | |
| SCHEMBL23268993 | 0.92 | BCL2 (0.85) | BCL2BECN1PKM | |
| SCHEMBL23268927 | 0.90 | BCL2 (1.00) | BCL2BECN1PKMALDH1A1MEN1 | |
| SCHEMBL23268968 | 0.90 | BCL2 (1.00) | BCL2BECN1PKMALDH1A1MEN1 | |
| SCHEMBL23268929 | 0.89 | BCL2 (0.81) | BCL2BECN1PKM | |
| SCHEMBL23268982 | 0.89 | BCL2 (1.00) | BCL2BECN1PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056601-A1 | PHARMACEUTICAL COMBINATION PRODUCT COMPRISING KINASE INHIBITOR AND AUTOPHAGY INDUCER AND USES THEREOF | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2025-03-20 | — | — | WO | claimed |
| US-20230203020-A1 | Small molecule inducers of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-29 | — | — | US | claimed |
| US-11591319-B2 | Small molecule inducers of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-28 | — | — | US | claimed |
| US-20220242854-A1 | Small molecule inducers of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-04 | — | — | US | claimed |
| WO-2025064402-A1 | METHOD FOR TREATING SICKLE CELL DISEASE BY TARGETING SENESCENT CELLS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025056601-A1 | PHARMACEUTICAL COMBINATION PRODUCT COMPRISING KINASE INHIBITOR AND AUTOPHAGY INDUCER AND USES THEREOF | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2025-03-20 | — | — | WO | disclosed |
| US-20230203020-A1 | Small molecule inducers of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203020-A1 | Small molecule inducers of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203020-A1 | Small molecule inducers of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-06-29 | — | — | US | disclosed |
| US-11591319-B2 | Small molecule inducers of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220242854-A1 | Small molecule inducers of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-04 | — | — | US | disclosed |
| US-11325898-B2 | Small molecule inducers of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325898-B2 | Small molecule inducers of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210115024-A1 | Small molecule inducers of autophagy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242854-A1 | Small molecule inducers of autophagy | BECN1, SQSTM1, MAP1LC3A | BCL2 102/4885BECN1 1/4885PKM 4148/4885 |
| US-11325898-B2 | Small molecule inducers of autophagy | BECN1, SQSTM1, MAP1LC3A | BCL2 11/4885BECN1 1/4885PKM 4064/4885 |
| US-11591319-B2 | Small molecule inducers of autophagy | BECN1, SQSTM1, MAP1LC3A | BCL2 102/4885BECN1 1/4885PKM 4148/4885 |
| US-20210115024-A1 | Small molecule inducers of autophagy | BECN1, SQSTM1, MAP1LC3A | BCL2 11/4885BECN1 1/4885PKM 4064/4885 |
| US-20230203020-A1 | Small molecule inducers of autophagy | BECN1, SQSTM1, MAP1LC3A | BCL2 11/4885BECN1 1/4885PKM 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.